AI Summary

Researchers at Mass General Brigham Heart and Vascular Institute reported that high‑risk patients without prior heart attacks or strokes experienced a lower mortality risk when treated with the cholesterol‑lowering drug evolocumab in addition to standard therapy, compared with placebo. The findings come from a clinical trial and were presented at the ESC Congress 2026 and published in the journal Circulation. This suggests that adding evolocumab may improve survival outcomes for this patient group.

AI summaries can be wrong sometimes—always verify important details using the source article.